cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 52, 2015, Pages E7176-E7185

  Lokireddy, Sudarsanareddy ^a   Kukushkin, Nikolay Vadimovich ^a   Goldberg, Alfred Lewis ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

CAMP; Camp dependent protein kinase; Proteasomes; Protein degradation; Rpn6 PSMD11

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; FORSKOLIN; FUSED IN SARCOMA PROTEIN; PHOSPHOPROTEIN PHOSPHATASE; PROTEASOME; PROTEIN KINASE; PSMD11 PROTEIN; ROLIPRAM; RPN6 PROTEIN; TAR DNA BINDING PROTEIN; TAU PROTEIN; UBIQUITINATED PROTEIN; UNCLASSIFIED DRUG; ATP DEPENDENT 26S PROTEASE; CYCLIC AMP; PHOSPHODIESTERASE IV INHIBITOR; PSMD11 PROTEIN, HUMAN; SERINE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN HYDROLYSIS; ANIMAL; CELL LINE; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; HUMAN; IMMUNOBLOTTING; METABOLISM; MUTATION; PHOSPHORYLATION; PROTEIN FOLDING; TUMOR CELL LINE;

ANIMALS; CELL LINE; CELL LINE, TUMOR; COLFORSIN; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HEK293 CELLS; HUMANS; IMMUNOBLOTTING; MUTATION; PHOSPHODIESTERASE 4 INHIBITORS; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN FOLDING; PROTEOLYSIS; ROLIPRAM; SERINE; VASODILATOR AGENTS;

EID: 84952685052     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1522332112     Document Type: Article

References (46)

1. Goldberg AL (2003) Protein degradation and protection against misfolded or damaged proteins. Nature 426(6968):895-899.
2. Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425-479.
3. Finley D (2009) Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu Rev Biochem 78:477-513.
4. Peth A, Uchiki T, Goldberg AL (2010) ATP-dependent steps in the binding of ubiquitin conjugates to the 26S proteasome that commit to degradation. Mol Cell 40(4):671-681.
5. Peth A, Kukushkin N, Bossé M, Goldberg AL (2013) Ubiquitinated proteins activate the proteasomal ATPases by binding to Usp14 or Uch37 homologs. J Biol Chem 288(11):7781-7790.
6. Peth A, Besche HC, Goldberg AL (2009) Ubiquitinated proteins activate the proteasome by binding to Usp14/Ubp6, which causes 20S gate opening. Mol Cell 36(5):794-804.
7. Goldberg AL (2012) Development of proteasome inhibitors as research tools and cancer drugs. J Cell Biol 199(4):583-588.
8. Sherman MY, Goldberg AL (2001) Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative diseases. Neuron 29(1):15-32.
9. Arrasate M, Finkbeiner S (2012) Protein aggregates in Huntington's disease. Exp Neurol 238(1):1-11.
10. Kristiansen M, et al. (2007) Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol Cell 26(2):175-188.
11. Bence NF, Sampat RM, Kopito RR (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292(5521):1552-1555.
12. Myeku N, et al. (2015) 26S proteasome dysfunction and cognitive impairment caused by aggregated tau accumulation can be attenuated by PKA-mediated phosphorylation of proteasomes. Nat Med, 10.1038/nm.4011.
13. Deriziotis P, et al. (2011) Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry. EMBO J 30(15):3065-3077.
14. Jucker M, Walker LC (2013) Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501(7465):45-51.
15. Zhang F, et al. (2003) O-GlcNAc modification is an endogenous inhibitor of the proteasome. Cell 115(6):715-725.
16. Cho-Park PF, Steller H (2013) Proteasome regulation by ADP-ribosylation. Cell 153(3):614-627.
17. Zhang F, et al. (2007) Proteasome function is regulated by cyclic AMP-dependent protein kinase through phosphorylation of Rpt6. J Biol Chem 282(31):22460-22471.
18. Bose S, Stratford FL, Broadfoot KI, Mason GG, Rivett AJ (2004) Phosphorylation of 20S proteasome alpha subunit C8(alpha7) stabilizes the 26S proteasome and plays a role in the regulation of proteasome complexes by gamma-interferon. Biochem J 378(Pt 1):177-184.
19. Ranek MJ, Terpstra EJ, Li J, Kass DA, Wang X (2013) Protein kinase g positively regulates proteasome-mediated degradation of misfolded proteins. Circulation 128(4):365-376.
20. Guo X, et al. (2011) UBLCP1 is a 26S proteasome phosphatase that regulates nuclear proteasome activity. Proc Natl Acad Sci USA 108(46):18649-18654.
21. Satoh K, Sasajima H, Nyoumura KI, Yokosawa H, Sawada H (2001) Assembly of the 26S proteasome is regulated by phosphorylation of the p45/Rpt6 ATPase subunit. Biochemistry 40(2):314-319.
22. Djakovic SN, et al. (2012) Phosphorylation of Rpt6 regulates synaptic strength in hippocampal neurons. J Neurosci 32(15):5126-5131.
23. Bingol B, et al. (2010) Autophosphorylated CaMKIIalpha acts as a scaffold to recruit proteasomes to dendritic spines. Cell 140(4):567-578.
24. Myeku N, Wang H, Figueiredo-Pereira ME (2012) cAMP stimulates the ubiquitin/proteasome pathway in rat spinal cord neurons. Neurosci Lett 527(2):126-131.
25. Lin JT, et al. (2013) Regulation of feedback between protein kinase A and the proteasome system worsens Huntington's disease. Mol Cell Biol 33(5):1073-1084.
26. Lira EC, et al. (2011) Phosphodiesterase-4 inhibition reduces proteolysis and atrogenes expression in rat skeletal muscles. Muscle Nerve 44(3):371-381.
27. Zhao J, et al. (2007) FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab 6(6):472-483.
28. Rock KL, et al. (1994) Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78(5):761-771.
29. Huss M, et al. (2002) Concanamycin A, the specific inhibitor of V-ATPases, binds to the V (o) subunit c. J Biol Chem 277(43):40544-40548.
30. Lang D, Fickenscher H, Stamminger T (1992) Analysis of proteins binding to the proximal promoter region of the human cytomegalovirus IE-1/2 enhancer/promoter reveals both consensus and aberrant recognition sequences for transcription factors Sp1 and CREB. Nucleic Acids Res 20(13):3287-3295.
31. Dantuma NP, Lindsten K, Glas R, Jellne M, Masucci MG (2000) Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat Biotechnol 18(5):538-543.
32. Park SJ, et al. (2012) Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148(3):421-433.
33. Besche HC, Goldberg AL (2012) Affinity purification of mammalian 26S proteasomes using an ubiquitin-like domain. Methods Mol Biol 832:423-432.
34. Peth A, Nathan JA, Goldberg AL (2013) The ATP costs and time required to degrade ubiquitinated proteins by the 26 S proteasome. J Biol Chem 288(40):29215-29222.
35. Smith DM, Fraga H, Reis C, Kafri G, Goldberg AL (2011) ATP binds to proteasomal ATPases in pairs with distinct functional effects, implying an ordered reaction cycle. Cell 144(4):526-538.
36. Perry G, Friedman R, Shaw G, Chau V (1987) Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc Natl Acad Sci USA 84(9):3033-3036.
37. McAllister FE, et al. (2013) Mass spectrometry based method to increase throughput for kinome analyses using ATP probes. Anal Chem 85(9):4666-4674.
38. Kinoshita E, Kinoshita-Kikuta E, Koike T (2009) Separation and detection of large phosphoproteins using Phos-tag SDS-PAGE. Nat Protoc 4(10):1513-1521.
39. Moreno D, Viana R, Sanz P (2009) Two-hybrid analysis identifies PSMD11, a non-ATPase subunit of the proteasome, as a novel interaction partner of AMP-activated protein kinase. Int J Biochem Cell Biol 41(12):2431-2439.
40. Vilchez D, et al. (2012) Increased proteasome activity in human embryonic stem cells is regulated by PSMD11. Nature 489(7415):304-308.
41. Vilchez D, et al. (2012) RPN-6 determines C. elegans longevity under proteotoxic stress conditions. Nature 489(7415):263-268.
42. Pathare GR, et al. (2012) The proteasomal subunit Rpn6 is a molecular clamp holding the core and regulatory subcomplexes together. Proc Natl Acad Sci USA 109(1):149-154.
43. Maurice DH, et al. (2014) Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 13(4):290-314.
44. Bruno O, et al. (2011) GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses. Br J Pharmacol 164(8):2054-2063.
45. Barad M, Bourtchouladze R, Winder DG, Golan H, Kandel E (1998) Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc Natl Acad Sci USA 95(25):15020-15025.
46. Vitolo OV, et al. (2002) Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: Reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci USA 99(20):13217-13221.